• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc REGN 3 Star

Last Price$454.50Day Change (%)1.37%
Open Price$448.04Day Change ($)6.12
Day Range448.04–460.1252-Week Range269.50–495.50

As of Fri 3/27/2015 5:00:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Regeneron Wins Expanded Approval for Eye Drug Elyea

    Regeneron Wins Expanded Approval for Eye Drug Elyea

  2. Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine

    Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluentâ„¢ (alirocumab) Published in The New England Journal of Medicine

  3. Amgen, Other Drug Company Shares Jump on Cholesterol Drug Findings

    Amgen, Other Drug Company Shares Jump on Cholesterol Drug Findings

  4. UPDATE: Amgen, other drug company shares jump on cholesterol drug findings

    UPDATE: Amgen, other drug company shares jump on cholesterol drug findings

  5. Amgen, other drug company shares jump on cholesterol drug findings

    Amgen, other drug company shares jump on cholesterol drug findings

  6. DJ Amgen, Other Drug Company Shares Jump on Cholesterol Drug Findings

    DJ Amgen, Other Drug Company Shares Jump on Cholesterol Drug Findings

  7. Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine

    Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluentâ„¢ (alirocumab) Published in The New England Journal of Medicine

  8. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

    Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.

  9. Research and Markets: B-Cell Chronic Lymphocytic Leukemia Pipeline Review 2015 - 18 Companies & 29 Drug Profiles

    Research and Markets: B-Cell Chronic Lymphocytic Leukemia Pipeline Review 2015 - 18 Companies & 29 Drug Profiles

  10. Research and Markets: Hyperlipidemia Pipeline Review 2015 - Featuring 25 Leading Companies

    Research and Markets: Hyperlipidemia Pipeline Review 2015 - Featuring 25 Leading Companies

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.